Perampanel for the control of glioma associated seizures efficacy and safety: a pilot phase II randomised controlled trial

Trial Profile

Perampanel for the control of glioma associated seizures efficacy and safety: a pilot phase II randomised controlled trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Perampanel (Primary) ; Levetiracetam
  • Indications Epilepsy; Glioma
  • Focus Therapeutic Use
  • Acronyms PEGASUS-1
  • Most Recent Events

    • 19 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 08 Jun 2017 Planned End Date changed from 31 Oct 2019 to 31 Mar 2020.
    • 08 Jun 2017 Planned initiation date changed from 28 Feb 2017 to 12 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top